CCR is expanding its efforts to identify and characterize the protein signatures of human cancer cells and tissues. Facilities housed at NCI-Frederick (NCI/SAIC Research Technology Program ) will be the focus for a Biomedical Research Proteomics Program that will emphasize the development of multidimensional techniques for the separation of cell and tissue proteins, and high-throughput, mass spectroscopy-based analytical approaches to support cancer research. This group, headed by Dr. Timothy Veenstra, will work in concert with the Clinical Proteomics Program, co-directed by Drs. Lance Liotta (NCI) and Emmanuel Petricoin (FDA). Clinical Proteomics will focus on translating proteomics technologies directly to patient diagnosis, toxicity monitoring, and therapeutic intervention.

Related Links:

Biomedical Proteomics Program
Mass Spectrometry Center , Analytical Chemistry Laboratory (ACL)
Separations Technology Group, ACL
Laboratory of Molecular Technology
Protein Chemistry Laboratory
Protein Expression Laboratory
NIH Laser Capture Microdissection Core